CX3CR1 and neoplasm: Antagonizing the CX3CR1:fractalkine pathway might attenuate CD8+ T cell-mediated inflammation in the omentum but secondary to this it might prevent the CX3CR1INT to CX3CR1NEG conversion and disrupt frequencies and migration of peripheral and central memory CD8+ T cells, which would also be detrimental to anti-tumor immunity.